BCIRG

AcronymDefinition
BCIRGBreast Cancer International Research Group
References in periodicals archive ?
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study.
Trial Arm HERA Chemo Chemo [right arrow] H NSABP AC [right arrow] P B-31 AC [right arrow] PH NCCTG AC [right arrow] P N9831 AC [right arrow] P [right arrow] H AC [right arrow] PH BCIRG 006 AC [right arrow] D AC [right arrow] DH DCarboH Trial Baseline LVEF HERA [less than or equal to] 55 NSABP LLN B-31 ([less than or equal to] 50) NCCTG LLN N9831 ([less than or equal to] 50) BCIRG 006 LLN ([less than or equal to] 50) Trial Severe CHF Contractile dysfunction HERA 0.
Un importante hallazgo del estudio BCIRG 006 es el beneficio con trastuzumab en terminos de SLE del subgrupo de mujeres con ganglios negativos.
Un aspecto relevante del estudio BCIRG 006 es su importante componente molecular.
The major new cardiotoxicity finding in BCIRG 006 was that the asymptomatic decline in left ventricular ejection fraction known to be induced by trastuzumab in a substantial portion of patients, is far more persistent than previously reported.
Others have reported that this reduction in heart function is typically reversed when trastuzumab is discontinued, but in the anthracycline/trastuzumab arm in BCIRG 006, the decline in ejection fraction persisted beyond 550 days in most cases.
BCIRG 006 randomized 3,222 patients with HER2-positive breast cancer and positive lymph nodes or other high-risk features to one of three treatment arms: a control group given a standard potent anthracycline-based chemotherapy regimen consisting of four cycles of doxorubicin and cyclophosphamide followed by four of docetaxel, the same regimen with the addition of 1 year of adjuvant trastuzumab beginning concurrent with the docetaxel, or a year of trastuzumab starting at the outset of six cycles of docetaxel and carboplatin.
Aventis Pharmaceuticals, the major sponsor of the BCIRG trials, provides funding and Taxotere free of charge for all patients.
BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients.
As some of the clinical trials on Herceptin (such as NSABP B-31, BCIRG 006, NCCTG 9831) mature, some of these pivotal validation studies can be completed.
Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study.